92 results on '"Reddel, Stephen W."'
Search Results
2. Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone
3. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease
4. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination
5. 8 Dosing of oral corticosteroid therapy and the risk of relapse at the onset of MOGAD
6. 9 Early and late clinical features in 171 patients with LGI1-antibody encephalitis
7. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
8. Two New Families and a Literature Review of ELOVL4-Associated Spinocerebellar Ataxia Type 34
9. Presumptive isolated neurosarcoidosis involving eloquent structures: An argument for empirical TNF-α inhibition
10. A family study and literature review of ELOVL4-associated spinocerebellar ataxia type 34
11. 2251 MGBase: ready, set, go! The launch of an international electronic database for patients with Myasthenia Gravis
12. Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to “overlap” cases
13. Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome
14. Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics
15. Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis
16. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
17. A dorsolateral medullary lesion causing persistent down-beating nystagmus
18. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy
19. Pregnancy without relapse following treated Susac syndrome
20. Vaping and e‐cigarettes: a life‐threatening hypersensitivity reaction
21. Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
22. The neuro-otology of Susac syndrome
23. Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
24. Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation
25. The clinical profile of NMOSD in Australia and New Zealand
26. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome
27. Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis
28. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus: Clues to early diagnosis
29. The spectrum of immune-mediated and inflammatory lesions of the brainstem
30. 072 Signal recognition particle antibody associated necrotizing myositis with ‘burnt-out’ paravertebral muscle atrophy
31. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
32. Pachymeningitis Demonstrated on Gallium SPECT/CT Scan
33. Clinical commentary on ‘Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis’
34. Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes)
35. Forearm-predominant parainfectious myositis
36. Warts and all: Fingolimod and unusual HPV-associated lesions
37. Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study
38. Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission
39. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
40. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure
41. A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers
42. Postnatal Development of Spasticity Following Transgene Insertion in the Mouse βIV Spectrin Gene (SPTBN4)
43. Incidence and prevalence of NMOSD in Australia and New Zealand
44. Development of an international electronic database for research into neuroimmunological diseases (enid)
45. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab
46. Variants in the Oxidoreductase PYROXD1 Cause Early-Onset Myopathy with Internalized Nuclei and Myofibrillar Disorganization
47. Extensive Postradiation Ocular and Diffuse Cranial Neuromyotonia Mimicking Myasthenia Gravis
48. Atypical inflammatory demyelinating syndromes of the CNS
49. Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3
50. Late presentations of congenital myasthenic syndromes: How many do we miss?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.